Babio Launches High-Accuracy Influenza A/B Antigen Detection Kit for Global Markets

With flu season impacting regions across Europe, North America, Africa, and Southeast Asia, rapid and accurate influenza detection has never been more critical. Babio Biotechnology (BABIO), a leading diagnostic manufacturer in China, introduces its Influenza A/B Antigen Detection Kit (Colloidal Gold Method), designed to deliver fast, reliable results within minutes.

Using advanced lateral flow immunoassay technology, the kit simultaneously detects Influenza A and Influenza B antigens in clinical specimens. Its clear T1 and T2 line system ensures accurate differentiation, while the integrated control line guarantees test validity.

The product offers high sensitivity, specificity, and user-friendly operation, making it ideal for hospitals, clinics, airports, and community health programs worldwide. With ISO-certified manufacturing and strict quality control, BABIO ensures consistent performance for mass screening and outbreak control.

For detailed specifications and ordering information, please visit www.babiomed.com.

#InfluenzaTest #RapidTestKit #BabioBiotech #FluDetection #ColloidalGold